Abstract
The inducible prostaglandin synthase cyclooxygenase-2 (Cox-2) is overexpressed in ∼40% of human breast cancers and at higher frequencies in preinvasive ductal carcinoma in situ (DCIS). Cox-2 expression is particularly associated with overexpression of human epidermal growth factor receptor 2 (HER2/neu). To definitively interrogate the role of Cox-2 in mammary neoplasia, we have used a genetic approach, crossing Cox-2-deficient mice with a HER2/neu transgenic strain, MMTV/NDL. At 20 weeks of age, mammary glands from virgin MMTV/NDL females contained multiple focal tumors, or mammary intraepithelial neoplasiae, which histologically resembled human DCIS. Mammary tumor multiplicity and prostaglandin E2 (PGE2) levels were significantly decreased in Cox-2 heterozygous and knockout animals relative to Cox-2 wild-type controls. Notably, the proportion of larger tumors was decreased in Cox-2-deficient mice. HER2/neu-induced mammary hyperplasia was also substantially reduced in Cox-2 null mice. Additionally, mammary glands from Cox-2 knockout mice exhibited a striking reduction in vascularization, and expression of proangiogenic genes was correspondingly reduced. Decreased vascularization was observed both in dysplastic and normal-appearing regions of Cox-2-null mammary glands. Our data provide the first genetic evidence that Cox-2 contributes to HER2/neu-induced mammary tumorigenesis. This finding may help to explain the reduced risk of breast cancer associated with regular use of nonsteroidal anti-inflammatory drugs.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10113-10119 |
| Number of pages | 7 |
| Journal | Cancer Research |
| Volume | 65 |
| Issue number | 21 |
| DOIs | |
| State | Published - Nov 1 2005 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. / Howe, Louise R.; Chang, Sung Hee; Tolle, Kelly C.; Dillon, Rachelle; Young, Lawrence J.T.; Cardiff, Robert; Newman, Robert A.; Yang, Peiying; Thaler, Howard T.; Muller, William J.; Hudis, Clifford; Brown, Anthony M.C.; Hla, Timothy; Subbaramaiah, Kotha; Dannenberg, Andrew J.
In: Cancer Research, Vol. 65, No. 21, 01.11.2005, p. 10113-10119.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice
AU - Howe, Louise R.
AU - Chang, Sung Hee
AU - Tolle, Kelly C.
AU - Dillon, Rachelle
AU - Young, Lawrence J.T.
AU - Cardiff, Robert
AU - Newman, Robert A.
AU - Yang, Peiying
AU - Thaler, Howard T.
AU - Muller, William J.
AU - Hudis, Clifford
AU - Brown, Anthony M.C.
AU - Hla, Timothy
AU - Subbaramaiah, Kotha
AU - Dannenberg, Andrew J.
PY - 2005/11/1
Y1 - 2005/11/1
N2 - The inducible prostaglandin synthase cyclooxygenase-2 (Cox-2) is overexpressed in ∼40% of human breast cancers and at higher frequencies in preinvasive ductal carcinoma in situ (DCIS). Cox-2 expression is particularly associated with overexpression of human epidermal growth factor receptor 2 (HER2/neu). To definitively interrogate the role of Cox-2 in mammary neoplasia, we have used a genetic approach, crossing Cox-2-deficient mice with a HER2/neu transgenic strain, MMTV/NDL. At 20 weeks of age, mammary glands from virgin MMTV/NDL females contained multiple focal tumors, or mammary intraepithelial neoplasiae, which histologically resembled human DCIS. Mammary tumor multiplicity and prostaglandin E2 (PGE2) levels were significantly decreased in Cox-2 heterozygous and knockout animals relative to Cox-2 wild-type controls. Notably, the proportion of larger tumors was decreased in Cox-2-deficient mice. HER2/neu-induced mammary hyperplasia was also substantially reduced in Cox-2 null mice. Additionally, mammary glands from Cox-2 knockout mice exhibited a striking reduction in vascularization, and expression of proangiogenic genes was correspondingly reduced. Decreased vascularization was observed both in dysplastic and normal-appearing regions of Cox-2-null mammary glands. Our data provide the first genetic evidence that Cox-2 contributes to HER2/neu-induced mammary tumorigenesis. This finding may help to explain the reduced risk of breast cancer associated with regular use of nonsteroidal anti-inflammatory drugs.
AB - The inducible prostaglandin synthase cyclooxygenase-2 (Cox-2) is overexpressed in ∼40% of human breast cancers and at higher frequencies in preinvasive ductal carcinoma in situ (DCIS). Cox-2 expression is particularly associated with overexpression of human epidermal growth factor receptor 2 (HER2/neu). To definitively interrogate the role of Cox-2 in mammary neoplasia, we have used a genetic approach, crossing Cox-2-deficient mice with a HER2/neu transgenic strain, MMTV/NDL. At 20 weeks of age, mammary glands from virgin MMTV/NDL females contained multiple focal tumors, or mammary intraepithelial neoplasiae, which histologically resembled human DCIS. Mammary tumor multiplicity and prostaglandin E2 (PGE2) levels were significantly decreased in Cox-2 heterozygous and knockout animals relative to Cox-2 wild-type controls. Notably, the proportion of larger tumors was decreased in Cox-2-deficient mice. HER2/neu-induced mammary hyperplasia was also substantially reduced in Cox-2 null mice. Additionally, mammary glands from Cox-2 knockout mice exhibited a striking reduction in vascularization, and expression of proangiogenic genes was correspondingly reduced. Decreased vascularization was observed both in dysplastic and normal-appearing regions of Cox-2-null mammary glands. Our data provide the first genetic evidence that Cox-2 contributes to HER2/neu-induced mammary tumorigenesis. This finding may help to explain the reduced risk of breast cancer associated with regular use of nonsteroidal anti-inflammatory drugs.
UR - http://www.scopus.com/inward/record.url?scp=27544512985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27544512985&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-05-1524
DO - 10.1158/0008-5472.CAN-05-1524
M3 - Article
C2 - 16267038
AN - SCOPUS:27544512985
VL - 65
SP - 10113
EP - 10119
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0099-7013
IS - 21
ER -